ACTA1 and colorectal carcinoma: SB emerges as a promising therapeutic candidate for inhibiting CAFs activation by downregulating key CAFs biomarkers α-SMA and POSTN, thus offering potential avenues for modulating fibroblast activation towards CAFs in CRC therapy.